U.S. Food and Drug Administration Names First Internal Cannabis Advisor
NEW YORK- According to an internal memo from earlier this week that an FDA spokesperson provided to the financial publication, MarketWatch, the U.S. Food and Drug Administration has appointed Norman Birenbaum, the former director of cannabis programs for New York State, as its first senior public health adviser on cannabis research and regulation initiatives.
Douglas C. Throckmorton, the FDA’s deputy center director for regulatory programs, said of Norman:
“With his expertise in policy analysis and legislative outreach related to cannabis and cannabis-derived products, Norman is excited about creating the high-value partnerships needed for FDA’s outreach throughout the health care community, including with patients and patient advocacy groups.
Under Governor Andrew Cuomo, Birenbaum oversaw the cannabis programs in New York State. In addition, he helped Rhode Island’s adult use cannabis sales get off the ground by serving as the organization’s first president.
Latest News
California Cannabis Brand, Rose, Teams Up with Kiva Sales and Service to Expand Product Line
LOS ANGELES-- Rose, California's cannabis brand, announced today an exclusive partnership with Kiva Sales and Service (KSS), a top sales and distribution platform that offers dispensaries a curated selection of the best brands in the ...
Australian Nurses Call for Medicinal Cannabis Education in Undergraduate Degrees
The group wants education about the endocannabinoid system included in undergraduate nursing degrees. Seven years ago, the Federal Parliament passed legislation to legalise medicinal cannabis in Australia. Since then, most cannabis medications have been classified ...
Psychedelic Firm Reunion Neuroscience Sues Mindset Pharma for Patent Infringement and Breach of Contract
LOS ANGELES-- Clinical research firm Reunion Neuroscience Inc. has filed a lawsuit against Mindset Pharma Inc. in federal court, alleging that the latter copied its psychedelic formula and presented it as its own invention while ...